Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Status:
Completed
Trial end date:
2018-08-13
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to evaluate signals of potential clinical
benefit of the combination of Verinurad and Febuxostat in lowering concentrations of
circulating uric acid and thus improving kidney or cardiovascular status of patients with
hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).